JANX007

About Janux Therapeutics

Janux Therapeutics is pioneering a new class of tumor-activated immunotherapies designed to overcome the limitations of traditional T-cell engagers, particularly their severe on-target, off-tumor toxicities. The company's proprietary platforms conditionally activate only in the tumor microenvironment, aiming to unlock the potential of powerful immunotherapies for solid tumors. With its lead candidate JANX007 in Phase 1 clinical trials for metastatic castration-resistant prostate cancer and a strong pipeline of other candidates, Janux is positioned at the forefront of next-generation immuno-oncology. The company went public in 2021 and is backed by a seasoned leadership team with deep experience in oncology drug development.

Therapeutic Areas

Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs